Peptide Library

Peptide Library

A curated reference database of 35 peptide profiles β€” evidence levels, benefits, administration routes, and safety information.

⚠️

Educational resource only. This library is provided for informational purposes. Not medical advice. Consult a licensed clinician before using any peptide. BioLabs does not supply, endorse, or recommend any of the substances listed.

Evidence
Benefits
Route

Showing 35 of 35 peptides

Semaglutide

GLP-1 Receptor Agonist

StrongRisk: Moderate
C187H291N45O59PubChem

A GLP-1 receptor agonist approved by regulatory agencies for type 2 diabetes and chronic weight management. Works by mimicking incretin hormones that regulate blood sugar and appetite.

πŸ”₯βš–οΈ
πŸ’‰ subQπŸ’Š oral
Semaglutide structure

Tirzepatide

GIP/GLP-1 Dual Agonist

StrongRisk: Moderate
C225H348N48O68PubChem

A dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management. Acts on two incretin hormone pathways to regulate blood sugar and reduce appetite.

πŸ”₯βš–οΈ
πŸ’‰ subQ
Tirzepatide structure

Tesamorelin

Egrifta (GHRH Analog)

StrongRisk: Moderate
C221H366N72O67SPubChem

An FDA-approved synthetic GHRH analog for reducing excess abdominal fat in HIV patients with lipodystrophy. Stimulates the pituitary gland to produce and release growth hormone.

πŸ”₯πŸ“ˆβš–οΈ
πŸ’‰ subQ
Tesamorelin structure

PT-141

Bremelanotide

StrongRisk: Moderate
C50H68N14O10PubChem

A melanocortin receptor agonist FDA-approved for treating hypoactive sexual desire disorder (HSDD) in premenopausal women. Acts through the central nervous system.

❀️
πŸ’‰ subQπŸ‘ƒ nasal
PT-141 structure

GHRP-6

Growth Hormone Releasing Peptide-6

ModerateRisk: Moderate
C46H56N12O6PubChem

A synthetic hexapeptide that stimulates growth hormone release from the pituitary gland. A first-generation growth hormone secretagogue known for its hunger-stimulating effects.

πŸ“ˆπŸƒπŸ”₯
πŸ’‰ subQπŸ’‰ IM
GHRP-6 structure

CJC-1295-DAC

Long-Acting GHRH Analog

ModerateRisk: Moderate
C152H252N44O42PubChem

A modified GHRH analog with an added Drug Affinity Complex (DAC) that extends its half-life, allowing for less frequent dosing compared to standard CJC-1295.

πŸ“ˆπŸƒπŸ”₯
πŸ’‰ subQ
CJC-1295-DAC structure

Ipamorelin

NNC 26-0161

ModerateRisk: Low
C38H49N9O5PubChem

A selective growth hormone secretagogue and ghrelin mimetic that stimulates growth hormone release without significantly affecting cortisol or prolactin levels.

πŸ“ˆπŸƒπŸ”₯
πŸ’‰ subQπŸ’‰ IM
Ipamorelin structure

AOD-9604

Advanced Obesity Drug

ModerateRisk: Low
C78H123N23O23S2PubChem

A modified fragment of human growth hormone (amino acids 176-191) developed to retain fat-reducing effects of HGH without growth-promoting effects.

βš–οΈπŸ”₯
πŸ’‰ subQ
AOD-9604 structure

Thymosin Alpha-1

TΞ±1

ModerateRisk: Low
C129H215N33O55PubChem

A thymic peptide approved in several countries for treating certain immune-related conditions. Research has explored its role in immune system modulation and cellular function.

πŸƒπŸ”₯
πŸ’‰ subQ
Thymosin Alpha-1 structure

GHK-Cu

Copper Peptide

ModerateRisk: Low
C14H22CuN6O4PubChem

A copper-binding peptide naturally found in human plasma, saliva, and urine. Extensively studied for skin health and wound healing, with some topical formulations commercially available.

βœ¨πŸƒ
🧴 topicalπŸ’‰ subQ
GHK-Cu structure

GHRP-2

Growth Hormone Releasing Peptide-2

ModerateRisk: Moderate
C45H55N9O6PubChem

A synthetic hexapeptide that stimulates growth hormone release from the pituitary gland. A second-generation growth hormone secretagogue with less hunger stimulation than GHRP-6.

πŸ“ˆπŸƒπŸ”₯
πŸ’‰ subQπŸ’‰ IM
GHRP-2 structure

Hexarelin

Examorelin

ModerateRisk: Moderate
C47H58N12O6PubChem

A synthetic hexapeptide and potent growth hormone secretagogue. Research has also explored its potential cardioprotective effects beyond growth hormone stimulation.

πŸ“ˆπŸƒπŸ”₯
πŸ’‰ subQπŸ’‰ IM
Hexarelin structure

NAD+

Nicotinamide Adenine Dinucleotide

ModerateRisk: Low
C21H27N7O14P2PubChem

A coenzyme central to cellular energy metabolism. Research has explored its potential role in cellular health, energy production, and age-related metabolic decline.

πŸ”₯πŸ§ πŸƒ
πŸ’‰ subQπŸ’‰ IMπŸ’Š oral
NAD+ structure

Oxytocin

Neuropeptide Hormone

ModerateRisk: Low
C43H66N12O12S2PubChem

A naturally occurring neuropeptide and hormone involved in social bonding, trust, and emotional regulation. Research has explored its potential in anxiety, autism spectrum disorder, and social function.

πŸ§ πŸƒ
πŸ‘ƒ nasalπŸ’‰ subQ
Oxytocin structure

Cerebrolysin

Neuropeptide Complex

ModerateRisk: Low
Complex MixturePubChem

A neuropeptide complex derived from porcine brain protein. Approved in some countries for neurological conditions. Research has explored its potential neuroprotective and neurorestorative properties.

🧠
πŸ’‰ IM
Cerebrolysin structure

BPC-157

Body Protection Compound-157

PreliminaryRisk: Unknown
C62H98N16O22PubChem

An experimental synthetic peptide derived from a protective stomach protein, frequently discussed in relation to soft-tissue recovery and gastrointestinal support. Human clinical data remains limited.

πŸƒπŸ¦ πŸ¦΄
πŸ’‰ subQπŸ’Š oral
BPC-157 structure

TB-500

Thymosin Beta-4

PreliminaryRisk: Unknown
C38H68N10O14PubChem

A synthetic version of the naturally occurring peptide Thymosin Beta-4, often discussed for its potential role in tissue repair and recovery. Robust human clinical evidence is sparse.

πŸƒπŸ¦΄
πŸ’‰ subQπŸ’‰ IM
TB-500 structure

CJC-1295 / Ipamorelin

GHRH + GHS Combination

PreliminaryRisk: Moderate
C152H252N44O42PubChem

CJC-1295 and Ipamorelin are peptides that stimulate the release of growth hormone. Often combined and discussed for potential effects on body composition, recovery, and sleep quality.

πŸ“ˆπŸƒπŸ”₯πŸ’€
πŸ’‰ subQ
CJC-1295 / Ipamorelin structure

Melanotan-2

MT-2

PreliminaryRisk: High
C50H69N15O9PubChem

A synthetic peptide analog of alpha-melanocyte stimulating hormone, discussed for its effects on skin pigmentation and libido. Not approved by major regulatory agencies; safety data is limited.

✨❀️
πŸ’‰ subQ
Melanotan-2 structure

MOTS-C

Mitochondrial-Derived Peptide

PreliminaryRisk: Unknown
C103H152N28O22S2PubChem

A mitochondrial-derived peptide that plays a role in metabolic regulation and cellular energy. A relatively new area of research exploring mitochondrial function and metabolic health.

πŸ”₯πŸƒπŸ§ 
πŸ’‰ subQπŸ’‰ IM
MOTS-C structure

IGF-1 LR3

Long R3 IGF-I

PreliminaryRisk: High
~C400H625N111O115S8PubChem

A modified version of insulin-like growth factor-1 with amino acid substitutions that extend its half-life and reduce binding to IGF binding proteins.

πŸ“ˆπŸƒπŸ”₯
πŸ’‰ subQπŸ’‰ IM
IGF-1 LR3 structure

KPV

Lys-Pro-Val Tripeptide

PreliminaryRisk: Unknown
C16H28N4O4PubChem

A tripeptide derived from alpha-melanocyte stimulating hormone (Ξ±-MSH). Research has explored its anti-inflammatory properties, particularly in the gastrointestinal tract.

πŸ¦ πŸƒ
πŸ’Š oralπŸ’‰ subQ
KPV structure

LL-37

Cathelicidin

PreliminaryRisk: Unknown
C205H340N60O53PubChem

A human antimicrobial peptide naturally produced by the body as part of the innate immune response. Research has explored antimicrobial properties and potential role in wound healing.

πŸƒπŸ¦ βœ¨
πŸ’‰ subQ🧴 topical
LL-37 structure

Follistatin-344

FS-344

PreliminaryRisk: Unknown
MacromoleculePubChem

A naturally occurring protein that binds to and inhibits myostatin, a protein that limits muscle growth. Research has explored its potential role in muscle development and metabolic regulation.

πŸ“ˆπŸƒ
πŸ’‰ subQπŸ’‰ IM
Follistatin-344 structure

5-Amino-1MQ

NNMT Inhibitor

PreliminaryRisk: Unknown
C11H13N2⁺PubChem

A small molecule that inhibits the enzyme NNMT (nicotinamide N-methyltransferase). Research has explored its potential effects on metabolism and energy expenditure in preclinical models.

βš–οΈπŸ”₯
πŸ’Š oralπŸ’‰ subQ
5-Amino-1MQ structure

HGH Fragment 176-191

Frag 176-191

PreliminaryRisk: Low
C78H123N23O23S2PubChem

A modified fragment of human growth hormone researched for its potential fat-reducing effects without the growth-promoting properties of full HGH. Closely related to AOD-9604.

βš–οΈπŸ”₯
πŸ’‰ subQ
HGH Fragment 176-191 structure

DSIP

Delta Sleep-Inducing Peptide

PreliminaryRisk: Unknown
C35H48N10O15PubChem

A neuropeptide first isolated in the 1970s. Research has explored its potential role in sleep regulation and stress response modulation, though human clinical evidence remains limited.

πŸ’€πŸƒ
πŸ’‰ subQπŸ’‰ IM
DSIP structure

SS-31

Elamipretide

PreliminaryRisk: Unknown
C32H49N9O5PubChem

A mitochondria-targeted peptide that stabilises the inner mitochondrial membrane. Research has explored its potential in conditions related to mitochondrial dysfunction and oxidative stress.

πŸ”₯πŸƒ
πŸ’‰ subQπŸ’‰ IM
SS-31 structure

VIP

Vasoactive Intestinal Peptide

PreliminaryRisk: Unknown
C147H237N43O43SPubChem

A neuropeptide that acts as a neuromodulator and neurotransmitter. Research has explored its role in immune regulation, gastrointestinal function, and inflammatory conditions.

πŸ¦ πŸƒπŸ”₯
πŸ‘ƒ nasalπŸ’‰ subQ
VIP structure

Humanin

Mitochondrial Peptide

PreliminaryRisk: Unknown
C119H204N34O32S2PubChem

A mitochondrial-derived peptide with cytoprotective properties. Research has explored its potential roles in cellular survival, metabolic regulation, and neuroprotection.

πŸ”₯πŸ§ πŸƒ
πŸ’‰ subQπŸ’‰ IM
Humanin structure

Epitalon

Epithalon

AnecdotalRisk: Unknown
C14H22N4O9PubChem

A synthetic tetrapeptide studied for its potential effects on the pineal gland and circadian rhythms. Research has explored its relationship with melatonin production and cellular aging markers.

πŸƒπŸ’€πŸ§ 
πŸ’‰ subQπŸ’‰ IM
Epitalon structure

Selank

TP-7 (Russia-approved anxiolytic)

AnecdotalRisk: Unknown
C33H57N11O9PubChem

A synthetic peptide developed in Russia based on the naturally occurring peptide tuftsin. Approved in Russia as an anxiolytic and nootropic, though experimental in most other countries.

πŸ§ πŸƒ
πŸ‘ƒ nasalπŸ’‰ subQ
Selank structure

Semax

ACTH(4-10) Fragment

AnecdotalRisk: Unknown
C37H51N9O10SPubChem

A synthetic peptide developed in Russia based on a fragment of ACTH. Approved in Russia as a nootropic and neuroprotective agent, though experimental in most other countries.

πŸ§ πŸƒ
πŸ‘ƒ nasalπŸ’‰ subQ
Semax structure

Dihexa

PNB-0408

AnecdotalRisk: Unknown
C27H44N4O5PubChem

A small peptide derived from angiotensin IV. Preclinical research has explored its potential role in cognitive enhancement and synaptic plasticity, though human data is very limited.

🧠
πŸ’Š oral🧴 topical
Dihexa structure

Pinealon

EDR Tripeptide

AnecdotalRisk: Unknown
C15H26N6O8PubChem

A synthetic tripeptide (Glu-Asp-Arg) studied in Russia for potential effects on the central nervous system and cellular aging. Evidence is primarily from preclinical and limited Russian clinical studies.

πŸ§ πŸ’€
πŸ’Š oralπŸ’‰ subQ
Pinealon structure

Partners & Associates

UK Urban Agritech
EISA
East Suffolk Council
Growspec Global
NutraGenesis
Solaris
OREX
Synergy Sphere
UK Urban Agritech
EISA
East Suffolk Council
Growspec Global
NutraGenesis
Solaris
OREX
Synergy Sphere
BioLabs

The Operating System for Biologicals

EIS Round 3 Open

Navigation

Registered Office

Centrum,
Norwich Research Park
Norwich, NR4 7UG, UK
Co. Reg.: 15812659

Sales & Distribution

Units 10, 11 & 16,
Nexus Power Park
Lowestoft, NR32 1XA

In Silico Lab

Scion House,
Stirling University
Innovation Park
Stirling, FK9 4NF
"BioLabsβ„’" is a Trading Style of Frontier Biolabs Ltd and Biolabs Corp Ltd
EISA Member Β· Knowledge Intensive Company

Regulatory Status

Biolabs Corp Ltd is authorised and regulated by the Financial Conduct Authority (Firm Reference Number: 1051225).

Regulatory Disclaimer

Biolabs Corp Ltd is listed on the FCA Financial Services Register under FRN 1051225. Check our registration details on register.fca.org.uk . Investment in early-stage ventures involves significant risk, including illiquidity, lack of dividends, loss of capital, and dilution.

Β© 2026 BioLabs. All rights reserved.